Ocular Surface Disease as an Immune-related Adverse Event of Immune Checkpoint Inhibitor Therapy.
PURPOSE Ocular surface disease, encompassing scleritis, episcleritis, keratitis, and sicca syndrome, is an increasingly recognized immune-related adverse event of immune checkpoint inhibitors (ICIs), yet its pharmacovigilance profile has not been systematically characterized across all approved ICI classes. We conducte...